Fondaparinux instructions for administration: Difference between revisions
(New page: Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Arixtra Injection is provided in a single dose, prefilled syringe...) |
No edit summary |
||
| Line 1: | Line 1: | ||
{{CMG}} | |||
==Instructions for Administration== | |||
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. | Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. | ||
Revision as of 03:38, 15 February 2009
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Instructions for Administration
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration.
Arixtra Injection is provided in a single dose, prefilled syringe affixed with an automatic needle protection system. Arixtra is administered by subcutaneous injection. It must not be administered by intramuscular injections. Arixtra is intended for use under a physician’s guidance. Patients may self-inject only if their physician determines that it is appropriate and with medical follow-up as necessary. Proper training in subcutaneous injection technique should be provided.
To avoid the loss of drug when using the pre-filled syringe, do not expel the air bubble from the syringe before the injection. Administration should be made in the fatty tissue, alternating injection sites (e.g., between the left and right anterolateral or the left and right posterolateral abdominal wall).
To administer Arixtra.
- Wipe the surface of the injection site with an alcohol swab.
- Twist the plunger cap and remove it.